MEOX2 and lung cancer: Finally, overall survival analysis of all INCAN lung cancer patients with EGFR-mutated status identified better overall survival prognosis with lower MEOX2 and GLI1 protein co-expression levels (p=0.024 and p=0.011, respectively) (Supplementary Figure 4A-4B), which is likely associated with combined-cisplatinum plus TKI-based treatments for a specific group (33/90) of EGFR-mutated lung cancer patients (Table II).